Get the Stockscreener App
1.36
0.01%
-0.000100
After Hours:
1.43
0.07
+5.15%
Plus Therapeutics Inc stock is traded at $1.36, with a volume of 19,367.
It is down -0.01% in the last 24 hours and up +4.62% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$1.3601
Open:
$1.45
24h Volume:
19,367
Relative Volume:
0.36
Market Cap:
$7.90M
Revenue:
-
Net Income/Loss:
$-13.32M
P/E Ratio:
-0.2259
EPS:
-6.02
Net Cash Flow:
$-13.01M
1W Performance:
+0.74%
1M Performance:
+4.62%
6M Performance:
-24.44%
1Y Performance:
-15.00%
1-Day Range:
$1.33
$1.45
1-Week Range:
$1.2894
$1.45
52-Week Range:
$1.145
$2.78
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire
Plus Therapeutics granted extension by Nasdaq - Investing.com
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire
Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World
Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart
Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions - The Malaysian Reserve
Prescription Digital Therapeutics for Mental Health: A New Era in Psychiatry - Psychiatry Advisor
SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle - STAT
Plus Therapeutics reports progress in brain cancer trial - Investing.com
Plus Therapeutics reports progress in brain cancer trial By Investing.com - Investing.com Canada
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting - ForexTV.com
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of ... - The Bakersfield Californian
Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings - Benzinga
The 3 Best Light Therapy Lamps of 2024 | Reviews by Wirecutter - The New York Times
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease - Frontiers
Elevar Therapeutics Resubmits New Drug Application to FDA - GlobeNewswire
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis - Yahoo Finance
Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World
Plus Therapeutics to present at CNS Annual Meeting By Investing.com - Investing.com Canada
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech
Plus Therapeutics to present at CNS Annual Meeting - Investing.com
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - StockTitan
Gilead Sciences Therapeutic Areas: Virology, Oncology & Inflammation - Gilead Sciences
Plus Therapeutics director buys $6k worth of shares By Investing.com - Investing.com Canada
Plus Therapeutics director buys $6k worth of shares - Investing.com
Plus Therapeutics director acquires $8.5k in stock - Investing.com
Plus Therapeutics director acquires $8.5k in stock By Investing.com - Investing.com Canada
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer - Yahoo Finance
Plus Therapeutics director buys $6.7k in company stock - Investing.com India
Petersen Greg buys $16,875 worth of Plus Therapeutics shares - Investing.com India
Petersen Greg buys $16,875 worth of Plus Therapeutics shares By Investing.com - Investing.com Australia
Elevar Therapeutics Reports Advances in HCC and Other - GlobeNewswire
Plus Therapeutics CEO buys $9.8k in company stock - Investing.com
With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights - STAT
Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial - STAT
Plus Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Plus Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Zenas, Bicara set out to raise $180M-plus in separate IPOs to fund autoimmune, cancer prospects - Fierce Biotech
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $20.00 at Ascendiant Capital Markets - Defense World
Plus Therapeutics stock sees reduced target after softer-than-expected Q2 results - Investing.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):